

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059, Gujarat, India.

Tele.: + 079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

June 18, 2026

To,
Dept. of Corporate Relations,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001
(Script Code: 544644)

To,
Dept. of Corporate Services,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra
Kurla Complex, Bandra (East), Mumbai- 400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Disclosure under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

With reference to the above captioned subject, please find enclosed herewith disclosure received from Invesco Asset Management (India) Private Limited under Regulation 29(1) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

Ref. No. SEBI / HM / SG / 007 / 2026

Jun 18, 2026

T: +91 22 6731 0000

E: mfservices@invescoindia.com

invescomutualfund.com

Corona Remedies Limited

Corona House, C, Mondeal Business Park,
Near Gurudwara, S. G. Highway,
Thaltej, Ahmedabad - 380059

Email: complianceofficer@coronaremedies.com

Kind Attn: Ms. Chetna Dharajiya, Company Secretary and Compliance Officer

Dear Madam,

**Sub: Reporting under Regulation 29(1) of SEBI (Substantial Acquisition of
Shares & Takeovers) Regulations, 2011**

In accordance with Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, we would like to inform you that the aggregate holding of certain schemes of Invesco Mutual Fund in the equity shares in Corona Remedies Limited ("**the Company**") as at close of business hours on Jun 17, 2026 was 5.0562% of the paid-up share capital of the Company.

In compliance with Regulation 29(1) and 29(3) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, please find enclosed details of acquisition in prescribed format in **Annexure 1** for disclosure to the company and stock exchanges where the shares of the Company are listed.

Kindly acknowledge receipt of the same.

Thanking You,

Sincerely,

For Invesco Asset Management (India) Pvt. Ltd.

**Hardik Mehta**
Chief Risk Officer

Encl: a/a.


CC:

Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400 051
Tel : 022 - 2659 8190, Fax : 022 - 2659 8191**Listing Department**
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 023
Fax : 022 - 2272 3121

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A - Details of the Acquisition

Name of the Target Company (TC)	Corona Remedies Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Invesco Mutual Fund under it's following scheme: • Invesco India Consumption Fund • Invesco India Smallcap Fund • Invesco India Large & Mid Cap Fund • Invesco India Midcap Fund • Invesco India Multicap Fund • Invesco India ELSS Tax Saver Fund		
Whether the acquirer belongs to Promoter / Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. BSE Limited 2. National Stock Exchange of India Limited		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable (*)	% w.r.t. total diluted share /voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	28,03,355	4.5836	NA
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	NA	NA
c) Voting rights (VR) otherwise than by shares	Nil	NA	NA
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	NA	NA
e) Total (a+b+c+d)	28,03,355	4.5836	NA
Details of acquisition			
a) Shares carrying voting rights acquired	2,89,017	0.4726	NA
b) VRs acquired otherwise than by equity shares	Nil	NA	NA
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	NA	NA
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	NA	NA
e) Total (a+b+c+-d)	2,89,017	0.4726	NA
After the acquisition, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	30,92,372	5.0562	NA
b) VRs otherwise than by equity shares	Nil	NA	NA
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying	Nil	NA	NA




Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

voting rights in the TC (specify holding in each category) after acquisition			
d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	NA	NA
e) Total (a+b+c+d)	30,92,372	5.0562	NA
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer / encumbrance, etc.)	Open Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA		
Date of acquisition of / date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	Jun 17, 2026		
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 61,16,00,880/- comprising of 6,11,60,088 equity shares of Re. 10/- each.		
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 61,16,00,880/- comprising of 6,11,60,088 equity shares of Re. 10/- each.		
Total diluted share/voting capital of the TC after the said acquisition	NA		

% w.r.t. total share capital is rounded off to four decimal places.

For Invesco Asset Management (India) Pvt. Ltd.

(Investment Manager for Invesco Mutual Fund)



Hardik Mehta
Chief Risk Officer

Date : Jun 18, 2026

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

**Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and
Takeovers) Regulations, 2011**

Part-B***

Name of the Target Company: Corona Remedies Limited

Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Whether the acquirer belongs to Promoter/ Promoter group	PAN of the acquirer and/or PACs
Invesco Mutual Fund under it's following scheme: • Invesco India Consumption Fund • Invesco India Smallcap Fund • Invesco India Large & Mid Cap Fund • Invesco India Midcap Fund • Invesco India Multicap Fund • Invesco India ELSS Tax Saver Fund	No	

For Invesco Asset Management (India) Pvt. Ltd.
(Investment Manager for Invesco Mutual Fund)



Hardik Mehta
Chief Risk Officer

Place: Mumbai
Date: Jun 18, 2026

Note:

(***) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.